You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Tipifarnib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Tipifarnib?

Tipifarnib is an investigational drug.

There have been 85 clinical trials for Tipifarnib. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2004.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are National Cancer Institute (NCI), Kura Oncology, Inc., and Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Recent Clinical Trials for Tipifarnib
TitleSponsorPhase
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung CancerKura Oncology, Inc.Phase 1
Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPNJiangbin Hospital Affiliated to Jiangsu UniversityPhase 2
Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPNJiangning Hospital Affiliated to Nanjing Medical UniversityPhase 2

See all Tipifarnib clinical trials

Clinical Trial Summary for Tipifarnib

Top disease conditions for Tipifarnib
trials0510152025LeukemiaLeukemia, MyeloidLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, Acute[disabled in preview]
Top clinical trial sponsors for Tipifarnib
trials0102030405060National Cancer Institute (NCI)Kura Oncology, Inc.Johnson & Johnson Pharmaceutical Research & Development, L.L.C.[disabled in preview]

See all Tipifarnib clinical trials

Tipifarnib: A Promising Drug Candidate in Oncology - Development Update and Market Projections

Introduction to Tipifarnib

Tipifarnib, also known as Zarnestra, is an oral, investigational drug candidate developed by Kura Oncology. It is a highly selective inhibitor of farnesyltransferase, an enzyme involved in the post-translational modification of proteins, including those with oncogenic potential[5].

Current Development Status

Head and Neck Squamous Cell Carcinoma (HNSCC)

Tipifarnib has shown significant promise in the treatment of patients with HRAS-mutant head and neck squamous cell carcinoma (HNSCC). The FDA has granted fast track designation to tipifarnib for this indication, particularly for patients who have progressed on platinum therapy. This designation is a result of the drug's compelling and durable anti-cancer activity observed in clinical studies[1][3].

In a phase II clinical trial presented at the AACR-NCI-EORTC International Conference, tipifarnib yielded durable objective responses in patients with recurrent and metastatic HNSCC harboring HRAS gene mutations. The trial demonstrated that tipifarnib could represent a targeted drug treatment personalized to the genomics of HNSCC patients’ tumors[3].

The ongoing registration-directed trial, AIM-HN, which began in November 2018, is expected to complete enrollment and provide further data on the efficacy and safety of tipifarnib in this patient population[1].

Urothelial Carcinoma

In addition to HNSCC, tipifarnib has also shown positive results in a phase 2 trial for HRAS mutant urothelial carcinoma. The trial met its primary endpoint of progression-free survival (PFS) rate at 6 months, with confirmed objective responses achieved in five of 13 evaluable patients. This proof-of-concept trial highlights the potential of tipifarnib in another challenging cancer type[2].

Peripheral T-Cell Lymphomas (PTCL)

Tipifarnib is currently in Phase III clinical development for the treatment of Peripheral T-Cell Lymphomas (PTCL). According to GlobalData, Phase III drugs for PTCL have a 75% phase transition success rate, indicating a favorable likelihood of approval for tipifarnib in this indication[4].

Safety and Tolerability

The safety profile of tipifarnib has been extensively evaluated in various clinical studies. While all patients in the HNSCC trial experienced at least one treatment-emergent adverse event (TEAE), the most frequently observed TEAEs greater than grade 3 included blood and lymphatic system disorders, gastrointestinal disorders, and renal disorders. However, these side effects have been manageable and consistent with the safety profile observed in prior studies[3].

Market Projections

Given the positive clinical data and the fast track designation from the FDA, tipifarnib is poised to make a significant impact in the oncology market.

Targeted Therapy Market

Tipifarnib's potential as a targeted therapy for HRAS-mutant cancers positions it well in a market that is increasingly moving towards personalized medicine. The success of genomic sequencing in identifying highly effective therapies tailored to specific tumor biology is likely to drive demand for drugs like tipifarnib[3].

Competitive Landscape

The oncology market is highly competitive, but tipifarnib's unique mechanism of action and its focus on specific genetic mutations could provide a competitive edge. As the drug progresses through its clinical trials and potentially gains regulatory approvals, it is likely to capture a significant share of the market for the treatment of HRAS-mutant cancers and other indications[1][4].

Patient Population and Unmet Need

Recurrent and metastatic HNSCC and other cancers with HRAS mutations represent a significant unmet medical need. Patients with these conditions often have limited treatment options and poor prognosis. The availability of a targeted therapy like tipifarnib could significantly improve outcomes for these patients, thereby driving market demand[3].

Key Takeaways

  • Fast Track Designation: Tipifarnib has received fast track designation from the FDA for the treatment of HRAS-mutant HNSCC.
  • Clinical Efficacy: The drug has shown durable objective responses and improved progression-free survival in clinical trials.
  • Safety Profile: Tipifarnib's safety profile is manageable, with side effects consistent with prior studies.
  • Market Potential: Tipifarnib is well-positioned in the targeted therapy market, particularly for HRAS-mutant cancers.
  • Ongoing Trials: The drug is in various stages of clinical development for HNSCC, urothelial carcinoma, and PTCL.

FAQs

Q: What is tipifarnib and how does it work? A: Tipifarnib is an oral, investigational drug candidate that inhibits farnesyltransferase, an enzyme involved in the post-translational modification of proteins, including those with oncogenic potential.

Q: What is the current development status of tipifarnib for HNSCC? A: Tipifarnib is in an ongoing registration-directed trial (AIM-HN) for HRAS-mutant HNSCC and has received fast track designation from the FDA.

Q: What other cancer types is tipifarnib being studied for? A: Besides HNSCC, tipifarnib is being studied for HRAS mutant urothelial carcinoma and is in Phase III for Peripheral T-Cell Lymphomas (PTCL).

Q: What are the common side effects of tipifarnib? A: Common side effects include blood and lymphatic system disorders, gastrointestinal disorders, and renal disorders, but these have been manageable in clinical studies.

Q: What is the market potential of tipifarnib? A: Tipifarnib has significant market potential as a targeted therapy for HRAS-mutant cancers, addressing an unmet medical need and offering personalized treatment options.

Sources

  1. FDA Grants Fast Track Designation to Tipifarnib for the Treatment of Patients with HRAS-mutant Head and Neck Squamous Cell Carcinoma. Cancer Network.
  2. Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma. Kura Oncology.
  3. Tipifarnib Shows Promising Clinical Activity in Patients With HRAS-mutant Head and Neck Cancer. American Association for Cancer Research.
  4. Tipifarnib by Kura Oncology for Peripheral T-Cell Lymphomas (PTCL). Pharmaceutical Technology.
  5. Pipeline | Kura Oncology. Kura Oncology.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.